Overview

• US biotechnology firm's fiscal Q1 net loss totaled $1.2 mln, EPS loss was $0.04

• Company advanced briquilimab clinical program, refiled Phase 2b protocol with FDA

• Jeet Mahal appointed CEO to lead next phase of clinical growth

Outlook

• Jasper plans to begin Phase 2b study of briquilimab in CSU in H2 2026, pending funding

• Company is seeking additional funding to start the planned Phase 2b study in CSU

• Jasper has refiled updated Phase 2b protocol with FDA for briquilimab in CSU

Result Drivers

• CLINICAL DEVELOPMENT COSTS - R&D expenses driven by advancement of briquilimab program and analysis of clinical data in CSU

• REGULATORY PREPARATIONS - Refiling of updated Phase 2b protocol with FDA as part of preparations for next clinical trial phase

Company press release: ID:nGNXbhs1Cc

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS		-$0.04
Q1 Net Income		-$1.2 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Jasper Therapeutics Inc is $6.50, about 606.4% above its May 13 closing price of $0.92

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.